Aberrant A2A receptor function in peripheral blood cells in Huntington's disease

被引:118
作者
Varani, K
Abbracchio, MP
Cannella, M
Cislaghi, G
Giallonardo, P
Mariotti, C
Cattabriga, E
Cattabeni, F
Borea, PA
Squitieri, F
Cattaneo, E
机构
[1] IRCCS Neuromed, Neurogenet Unit, I-86077 Pozzilli, IS, Italy
[2] Univ Ferrara, Dept Clin & Expt Med, Pharmacol Unit, I-44100 Ferrara, Italy
[3] Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy
[4] Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy
[5] Fornaroli Hosp, Neurol Sect, Magenta, MI, Italy
[6] IRCCS C Besta, Neurogenet Sect, Milan, Italy
关键词
A(2A) adenosine receptor; blood circulating cells; Huntington's disease; biomarker;
D O I
10.1096/fj.03-0079fje
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A(2A) adenosine receptors specifically found on striatal medium spiny neurons play a major role in sensory motor function and may also be involved in neuropsychiatric and neurodegenerative disorders. One hypothesis concerning Huntington's disease (HD) proposes that an imbalance of the cortico-striatal pathway, due to the mutation in the HD gene, leads to striatal vulnerability. An A(2A) receptor dysfunction has been previously demonstrated in striatal cells engineered to express mutant huntingtin. Here we tested whether a similar dysfunction (i.e., the binding and functional parameters of A(2A) adenosine receptors) is present in peripheral blood cells (platelets, lymphocytes, and neutrophils) of subjects carrying the mutant gene. This study involved 48 heterozygous and three homozygous patients compared with 58 healthy subjects. Moreover, we selected seven at-risk mutation carriers. A(2A) receptor density and function are substantially increased in peripheral blood cells from both patients and subjects at the presymptomatic stage. In the neutrophils of the three homozygous HD subjects receptor dysfunction was higher than in heterozygotes. These data indicate the existence of an aberrant A(2A) receptor phenotype in the peripheral blood cells of subjects carrying the HD mutation. Future studies will assess whether this parameter can be exploited as a peripheral biomarker of Huntington's disease.
引用
收藏
页码:2148 / +
页数:16
相关论文
共 39 条
[21]   LIGAND - A VERSATILE COMPUTERIZED APPROACH FOR CHARACTERIZATION OF LIGAND-BINDING SYSTEMS [J].
MUNSON, PJ ;
RODBARD, D .
ANALYTICAL BIOCHEMISTRY, 1980, 107 (01) :220-239
[22]  
PARSONS B, 1995, J NEUROCHEM, V65, P2057
[23]   Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity:: Possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum [J].
Popoli, P ;
Pintor, A ;
Domenici, MR ;
Frank, C ;
Tebano, MT ;
Pèzzola, A ;
Scarchilli, L ;
Quarta, D ;
Reggio, R ;
Malchiodi-Albedi, F ;
Falchi, M ;
Massotti, M .
JOURNAL OF NEUROSCIENCE, 2002, 22 (05) :1967-1975
[24]  
Rovati GE, 1998, TRENDS PHARMACOL SCI, V19, P365
[25]   Lessons from animal models of Huntington's disease [J].
Rubinsztein, DC .
TRENDS IN GENETICS, 2002, 18 (04) :202-209
[26]   Midazolam selectively potentiates the A2A- but not A1-receptor-mediated effects of adenosine [J].
Seubert, CN ;
Morey, TE ;
Martynyuk, AE ;
Cucchiara, RF ;
Dennis, DM .
ANESTHESIOLOGY, 2000, 92 (02) :567-577
[27]  
Sipione S, 2001, MOL NEUROBIOL, V23, P21
[28]   Onset and pre-onset studies to define the Huntington's disease natural history [J].
Squitieri, F ;
Cannella, M ;
Giallonardo, P ;
Maglione, V ;
Mariotti, C ;
Hayden, MR .
BRAIN RESEARCH BULLETIN, 2001, 56 (3-4) :233-238
[29]   DNA HAPLOTYPE ANALYSIS OF HUNTINGTON DISEASE REVEALS CLUES TO THE ORIGINS AND MECHANISMS OF CAG EXPANSION AND REASONS FOR GEOGRAPHIC VARIATIONS OF PREVALENCE [J].
SQUITIERI, F ;
ANDREW, SE ;
GOLDBERG, YP ;
KREMER, B ;
SPENCE, N ;
ZEISLER, J ;
NICHOL, K ;
THEILMANN, J ;
GREENBERG, J ;
GOTO, J ;
KANAZAWA, I ;
VESA, J ;
PELTONEN, L ;
ALMQVIST, E ;
ANVRET, M ;
TELENIUS, H ;
LIN, B ;
NAPOLITANO, G ;
MORGAN, K ;
HAYDEN, MR .
HUMAN MOLECULAR GENETICS, 1994, 3 (12) :2103-2114
[30]   Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course [J].
Squitieri, F ;
Gellera, C ;
Cannella, M ;
Mariotti, C ;
Cislaghi, G ;
Rubinsztein, DC ;
Almqvist, EW ;
Turner, D ;
Bachoud-Lévi, AC ;
Simpson, SA ;
Delatycki, M ;
Maglione, V ;
Hayden, MR ;
Di Donato, S .
BRAIN, 2003, 126 :946-955